Relmada Therapeutics reports Q4 2025 earnings results. The biotech company, led by CEO Sergio Traversa, held its earnings conference call on March 19, 2026, discussing financial performance for the fourth quarter and full year 2025. The call included participation from major investment firms including Jefferies, Mizuho Securities, and Piper Sandler analysts. Management presented business updates and outlined the company's financial results for the periods ended December 31, 2025. Relmada's leadership team, including Chief Financial Officer Maged Shenouda and Chief Medical Officer of Urology Raj Pruthi, addressed investor questions regarding company performance and strategic direction. The earnings call transcript provides detailed insights into the company's operational and financial developments throughout 2025.
Post from MarketNews_en
Log in to interact with content.